Assenagon Asset Management S.A. Buys 37,139 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Assenagon Asset Management increased its Regeneron stake by 17.9%, purchasing 37,139 additional shares to own 244,927 shares valued at approximately $152.7 million. Institutional investors collectively own 83.31% of REGN.
• Regeneron reported strong quarterly results, with EPS of $14.29 versus the $10.16 consensus and revenue of $4.29 billion, up 16.7% year over year. The company also declared a quarterly dividend of $0.94 per share, representing a 0.5% annualized yield.
• Analysts maintain a generally positive outlook, with a “Moderate Buy” consensus rating and an average price target of $797.75, although the company faces potential legal risks related to allegations concerning its failed Phase 3 Fianlimab-Libtayo study.

Assenagon Asset Management S.A. lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 17.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 244,927 shares of the biopharmaceutical company's stock after purchasing an additional 37,139 shares during the period. Assenagon Asset Management S.A. owned approximately 0.23% of Regeneron Pharmaceuticals worth $152,722,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of REGN. Vanguard Group Inc. lifted its holdings in Regeneron Pharmaceuticals by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 9,075,153 shares of the biopharmaceutical company's stock worth $7,004,838,000 after buying an additional 26,884 shares in the last quarter. Dodge & Cox raised its position in shares of Regeneron Pharmaceuticals by 1.0% during the fourth quarter. Dodge & Cox now owns 4,596,358 shares of the biopharmaceutical company's stock worth $3,547,791,000 after acquiring an additional 45,513 shares during the last quarter. Franklin Resources Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 4.4% during the fourth quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company's stock valued at $1,975,990,000 after acquiring an additional 106,861 shares during the period. Nuveen LLC boosted its holdings in Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company's stock valued at $1,551,858,000 after acquiring an additional 835,240 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Regeneron Pharmaceuticals by 142.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company's stock valued at $1,504,991,000 after acquiring an additional 1,144,887 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Trading Up 0.5%

NASDAQ:REGN opened at $772.11 on Friday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $541.00 and a 1-year high of $821.11. The business's 50-day moving average price is $653.89 and its two-hundred day moving average price is $711.82. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $81.63 billion, a price-to-earnings ratio of 19.08, a PEG ratio of 1.35 and a beta of 0.22.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company's revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period in the previous year, the company earned $12.81 EPS. On average, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 43.11 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 9.29%.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 200 shares of the business's stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the transaction, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company's stock.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Improving earnings estimates suggest analysts see potential upside for REGN, supporting the recent share-price recovery. Surging Earnings Estimates Signal Upside for Regeneron Stock
• Positive Sentiment: Guggenheim raised its price target on Regeneron to $1,030, indicating substantial potential appreciation from recent trading levels and reinforcing the bullish case. Guggenheim Increases Regeneron Price Target
• Neutral Sentiment: Citigroup increased its price target to $740. While the revision is positive, the target remains below recent trading levels, signaling a more cautious view than Guggenheim’s. Citigroup Raises Regeneron Price Target
• Negative Sentiment: Several law firms are soliciting investors to lead or participate in a securities class action alleging that Regeneron made misleading statements about the prospects of its Phase 3 Fianlimab-Libtayo study in advanced melanoma. The lawsuit follows the trial failure and an earlier sharp decline in REGN’s value; the allegations have not been proven. Regeneron Investor Class Action Alert
• Negative Sentiment: The legal notices set a September 14, 2026 deadline for investors seeking lead-plaintiff status, keeping the failed trial and potential disclosure-related liabilities in focus. SueWallSt Regeneron Class Action Deadline

Wall Street Analysts Forecast Growth

REGN has been the subject of several recent research reports. Wells Fargo & Company boosted their price objective on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an "equal weight" rating in a report on Friday, July 31st. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 24th. Leerink Partners reiterated a "market perform" rating and set a $641.00 price target (down from $792.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, May 18th. Citigroup boosted their price target on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a "neutral" rating in a research note on Monday. Finally, Sanford C. Bernstein upgraded shares of Regeneron Pharmaceuticals to a "hold" rating in a report on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and ten have given a Hold rating to the company's stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $797.75.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source